Phase 1 N=24 Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel® on Healthy Subjects.
Dry Eye · Dry Eye Syndrome of Unspecified Lacrimal Gland
Primary: Goblet Cell Density (GCD) — 444; 440 cells/mm^2 — p=0.285
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=964 Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"
Type 2 Diabetes Mellitus
Primary: Percentage of Participants Who Had One or More Adverse Reactions — 5.41; 1.20; 0.98; 0.00 Percentage of Participants
N/A N=40 Recovery Enhancement and Sleep Training
Sleep · Performance · Mental Health
Primary: Pittsburgh Sleep Quality Index ( PSQI) — 4.941176471; 6.555555556; 4.647058824; 5.833333333 units on a scale
Phase 1 N=26 A Study of Two Dosage Forms of LY2886721 in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY2886721 — 183; 195; 181; 173 nanograms / milliliter (ng/mL)
Phase 1 N=30 Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects
Dry Eye Syndromes · Lubricant Allergy · Tear Disorder
Primary: Goblet Cell Density (GCD) — 282.5; 326.8; 291.5 cells/mm2 — p=0.273
N/A N=20 Music Intervention on Migraine Headaches
Migraine Headache
Primary: Frequency of Migraine Attacks (Number of Days Per Month) — 8.45; 5.65 Number of migraine per months — p=0.012
N/A N=414 Preparing Older Veterans With Serious and Chronic Illness for Decision Making
Aging
Primary: New Advance Care Planning Documentation in the Medical Record at 9 Months — 35; 25 percentage of participants
Phase 2 N=36 A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
Asymptomatic Hyperuricemia
Primary: Change From Baseline in Peak Urinary Excretion of Uric Acid (UA) on Day 7 — -12.87; -13.15 milligrams (mg)
Phase 4 N=56 Mechanisms of Lipodystrophy in HIV-Infected Pateints
HIV Infections
Primary: Effect of Drug Regimens on Serum Triglycerides. — 228.0; 230.4; 293.4; 290.0 mg/dL — p=0.94
Phase 4 N=208 Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
Relapsing-Remitting Multiple Sclerosis
Primary: Number of Participants With Adverse Events (AEs) — 107; 100; 44; 38 participants
Phase 4 N=188 Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
Rhinitis, Allergic, Seasonal · Asthma
Primary: Change From Baseline in Morning (AM) and Evening (PM) Total Asthma Symptom Severity (TASS) — 6.5; 5.9; -0.9; -1.4 Score on a scale — p=0.101
Phase 1 N=20 Rimeporide in Patients With Duchenne Muscular Dystrophy
Muscular Dystrophy, Duchenne
Primary: Number of Participants With Adverse Events — 2; 1; 5; 4 Participants
Phase 3 N=214 A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
Prostate Neoplasms
Primary: DB Phase: Time to Prostate-Specific Antigen Progression (PSA) — 84.00; 169.00 Days — p=0.0002
Phase 1 N=9 Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients
Healthy Volunteers · Breast Cancer
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0 Participants
Phase 4 N=387 A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain
Pain, Postoperative
Primary: Time to First Use of Rescue Medication — 1.22; 1.22; 1.18; 11.017 hours — p=<0.001